The cationic nanoliposomes loaded with asymmetric PCR product targeting PTK6 mRNA and induce apoptosis in PANC-1 cells Authors: Reyhane Fooladi Vayqan, Maliheh Entezari, Raziye Tajali, Neda Zali, Ali Jebali, Amir Sadeghi, Mehrdad Hashemi Published: 2026 ABSTRACT Protein tyrosine kinase 6 (PTK6/BRK) is implicated in tumor cell survival and has emerged as a potential therapeutic target in pancreatic cancer. Here, the aim of this study was to evaluate the cationic nanoliposomes loaded with asymmetric PCR product (CNLAPCRP) targeting PTK6 in pancreatic cancerous cells (PANC-1) than on pancreatic non-cancerous cells (HPDE-C7). Here, an antisense single‑stranded DNA complementary to the PTK6 coding sequence was generated by asymmetric PCR, purified, and encapsulated into cationic nanoliposomes. Their particle size, morphology, and surface charge were characterized. Both PANC-1 and HPDE-C7 cells were exposed to CNLAPCRP (0, 0.1, 1, and 10 µg/mL), Asymetric PCR product alone (0, 0.1, 1, and 10 µg/mL), nanoliposome alone, and PBS as negative control for 24, 48, and 72 h. Finally, the cell viability (MTT), apoptosis (flow cytometry), and western bloting were assessed done for all study groups. The CNLAPCRPs were near-spherical (30–120 nm; mean ~ 60 nm) with a zeta potential of ~ + 25 mV. Here, we found that CNLAPCRP effectively reduced PANC-1 cell viability, induces apoptosis, and decreased ptk6 protein level. The most important finding was that CNLAPCRP had a much greater effect on cancerous cells (PANC-1) than on non-cancerous cells (HPDE-C7), indicating targeted manner of CNLAPCRP. While these data support the biological activity of the CNLAPCRP, direct demonstration of PTK6 knockdown and inclusion of sequence‑matched and formulation controls are needed to confirm target-specific gene silencing and to delineate the mechanism. Further in‑depth characterization and in vivo evaluation are warranted.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-51586-9. Introduction Pancreatic adenocarcinoma (PAAD) is among the most delicate solid malignancies, largely because of its late onset, rapid progression, and lack of effective therapeutic options1,2. Standard treatments only slightly improve survival, and current biomarkers are not sensitive or specific enough for early detection. These facts highlight the need for precision modalities and novel molecular targets that can inhibit PAAD’s carcinogenic signaling pathways3. The PTK6 gene, also referred to as Breast Tumor Kinase (BRK), encodes a non-receptor cytoplasmic tyrosine kinase primarily found in differentiated epithelial tissues. This protein features three structural domains—SH3, SH2, and a catalytic kinase domain—that allow it to interact with a diverse array of intracellular signaling molecules4. PTK6 expression is normally restricted to mature and differentiated tissues, where it is essential for processes like cell migration, survival, stress response, differentiation, and growth. However, studies show that PTK6 expression is markedly upregulated in colorectal, breast, prostate, esophageal, and pancreatic cancers, among other cancer types5–9. Its upregulation has been linked to tumor formation, cancer progression, increased cell motility, and metastasis9. Mechanistically, PTK6 advances the development of cancer by activating important oncogenic signaling pathways, such as β-catenin10, AKT11, STAT37, and ERK1/29. It is therefore becoming more widely acknowledged as a potential therapeutic target for controlling the spread of particular cancers12. Antisense strategies have emerged as a powerful gene silencing approach, employing short sequence-specific molecules that bind complementary mRNAs to suppress translation13. Instead of employing chemically synthesized antisense oligonucleotides, here we generated an antisense single-stranded DNA fragment complementary to the PTK6 coding sequence using asymmetric PCR. Such PCR-derived antisense molecules can specifically bind target mRNA and suppress expression, offering a low-cost and sequence-specific silencing approach13. Efficient intracellular delivery remains a major barrier to nucleic acid therapeutics. Lipid-based nanoparticles, including nanoliposomes, are among the most widely used carriers due to their biocompatibility, ability to encapsulate hydrophilic cargo, and amenability to surface and compositional optimization14. Clinically validated lipid systems have demonstrated the feasibility of systemic nucleic acid delivery, yet challenges persist—particularly stability in biologic fluids, control of size and polydispersity, encapsulation efficiency, and endosomal escape—all of which can influence potency and safety profiles15. Optimizing these parameters is essential for robust, sequence-specific activity in cancer cells. In this study, we developed a cationic nanoliposomes loaded with asymmetric PCR product (CNLAPCRP) targeting PTK6 gene. We investigated its physicochemical properties and evaluated its ability to silence PTK6 in pancreatic cancerous cells (PANC-1) than on pancreatic non-cancerous cells (HPDE-C7). This approach integrates a novel antisense DNA generation method with a clinically relevant delivery platform. The goal is to create a basis for sequence-specific PTK6 inhibition in pancreatic cancer. The present study introduces a novel integrated strategy that combines asymmetric PCR–generated antisense single-stranded DNA targeting PTK6 with a cationic nanoliposomal delivery system. To the best of our knowledge, this is the first study to encapsulate an asymmetric PCR product targeting PTK6 mRNA into cationic nanoliposomes and to systematically evaluate its physicochemical properties alongside its biological effects on both pancreatic cancerous (PANC-1) and non-cancerous (HPDE-C7) cells (Fig. 1). By simultaneously assessing cell viability, apoptosis induction, and PTK6 protein expression, this work establishes a direct link between nanocarrier design and functional modulation of oncogenic signaling. The observed preferential activity of the formulated nanoliposomes in cancerous cells further highlights the potential of this approach as a selective and translational gene-targeting platform for pancreatic cancer therapy. Fig. 1Cationic nanoliposomes loaded with asymmetric PCR product (CNLAPCRP) reduce cell viability and induce apoptosis in PANC-1 cells compared with HPDE-C7. Cationic nanoliposomes loaded with asymmetric PCR product (CNLAPCRP) reduce cell viability and induce apoptosis in PANC-1 cells compared with HPDE-C7. Materials and methods Bioinformatic analysis The UALCAN database was used to evaluate PTK6 mRNA and protein expression in pancreatic cancer versus normal tissues. Pan-cancer expression profiles were also examined. Boxplots and CPTAC-based protein data were generated to assess statistical significance (p < 0.05). Cell culture The pancreatic cancerous cells (PANC-1) than on pancreatic non-cancerous cells (HPDE-C7) were obtained from the National Cell Bank of Iran (Pasteur Institute, Tehran, Iran). The cells were cultured in DMEM (Gibco, USA) containing 10% fetal bovine serum (FBS), 1% penicillin-streptomycin (Dna Biotech co, Iran), and incubated at 37 °C in a humidified atmosphere containing 5% CO2. Cells were sub-cultured at ~ 70–80% confluence using 0.25% trypsin–EDTA (Gibco, USA)16. Molecular biology method Primer design Primer-BLAST (NCBI) was used to design primers that target the coding sequence (CDS) of the human PTK6 gene (GenBank accession: NM_005975.4). The forward primer, 5′-ATGGTGTCCCGGGACCAG-3′, was selected as a complementary 18–24 nucleotide sequence from the 5′ end of the CDS, and the reverse primer, 5′-TCAGGTCGGGTTCTCGTA-3′, was chosen as an 18–24 nucleotide sequence from the 3′ end. Both primers were optimized for a GC content of approximately 50%, a melting temperature (Tm) of 60 °C ± 2 °C, and the absence of predicted secondary structures such as hairpins or primer dimers. These primers were subsequently used in asymmetric PCR to preferentially amplify single-stranded DNA corresponding to the antisense strand, which served as the PTK6-targeting antisense oligonucleotide. RNA extraction and cDNA synthesis Total RNA was extracted from untreated PANC-1 cells using RNX PLUS reagent (CinnaGen, Iran), following the manufacturers protocol17. RNA purity and concentration were assessed using NanoDrop spectrophotometry (260/280 and 260/230 ratios within 1.8–2.2 were considered acceptable). First-strand cDNA was synthesized from 1 µg total RNA using M-MuLV Reverse Transcriptase (Thermo Fisher Scientific, USA) and Oligo (dT) primers18. The resulting cDNA served as the template for asymmetric PCR. Asymmetric PCR product Asymmetric PCR was performed using the designed primer pair in a primer ratio favoring the reverse primer (50:1) to generate single-stranded antisense DNA. Reaction components included 10 µL PCR master mix, 5 µL cDNA template, 1 µL of forward primer (2 µM), 1 µL of Reverse primer (100 µM), and 3 µL nuclease-free water in a total volume of 20 µL. Thermal cycling conditions were: 95 °C for 2 min; 35–40 cycles of 95 °C for 15 s, 60 °C for 30 s, 72 °C for 30 s; final extension 72 °C for 3 min. Amplified products were verified on 2% agarose gel, purified using a spin column (Cinaclone, Iran), and quantified via NanoDrop. Nanoliposome synthesis and characterization To synthesize CNLAPCRP, 100 µL of Asymmetric PCR product (100 ng) was added to 1 mL of cationic emulsifiers (DOSPA : DOPE 3:1) and mixed, without any mechanical or chemical elements, for 5 min at room temperature. The product was centrifuged at 10,000 RMP for 5 min and the optical density of supernatant was read by a NanoDrop (Nanozyst, Iran) at 260 nm to measure loading efficiency. Loading percentage = (Optical density of supernatant − Optical density of the purified Asymetric PCR) / Optical density of the purified Asymetric PCR × 100. The size distribution, polydispersity index (PDI), and surface charge of the synthesized nanoliposomes, CNLAPCRP, were evaluated using dynamic light scattering (DLS) (Malvern, UK) and their morphology was assessed by Transmission Electron Microscopy (TEM) (Zeiss, Japan)19. To assess the stability of the synthesized liposomes, their size distribution, surface charge, and release were measured during 4 weeks to assess their leakage and for how long DNA was retained in the liposomes. Cell treatment and functional assay Cell treatment In this study, cells were prepared in different plate formats depending on the type of analysis. For MTT assays, cells were seeded into 96-well plates at a density of 10,000 cells per well. For apoptosis and protein analysis, 2–5 × 10⁵ cells were seeded per well in 6-well plates. Both PANC-1 and HPDE-C7 cells were exposed to CNLAPCRP (0, 0.1, 1, and 10 µg/mL), Asymetric PCR product alone (0, 0.1, 1, and 10 µg/mL), nanoliposome alone, and PBS as negative control for 24, 48, and 72 h. Here, we removed any unencapsulated DNA for all experiments by ultracentrifugation at 10,000 RPM at 10 min.For apoptosis and western bloting incubation time was 48 h. MTT assay After treatment, 100 µL of MTT (100 µg/mL, Sigma, USA) was added per well and incubated 3 h at 37 °C. Formazan crystals were dissolved with 100 µL DMSO, and absorbance was measured at 570 nm. Cell viability (%) was calculated as: Cell viability (%) = (Optical density of test group / Optical density of control group) × 10020. Here, PBS treated group was considered as the negative control. Apoptosis assay (Annexin V–FITC/PI) Apoptosis was evaluated using Annexin V–FITC/PI staining (BD Biosciences, USA). After being harvested, treated cells were resuspended in 100 µL of binding buffer and cleaned with PBS. Annexin V-FITC (2.5 µL) and propidium iodide (2.5 µL) were added, incubated 15 min in the dark, and analyzed by flow cytometry. Live cell, Early apoptotic cells, Late apoptotic cells, and Necrotic cells were quantified for each study group using FlowJo™ software (Version 10.8, Becton, Dickinson and Company, 2021)21. Western blotting The proteins were extracted using RIPA lysis buffer (Thermo Fisher Scientific, USA). Proteins were resolved by SDS-PAGE, and transferred to PVDF membranes (Sigma Aldrich, USA). Membranes were blocked with 5% BSA. Antibodies to the PTK6 and to GAPDH were obtained from (Abcam, USA), respectively. Membranes were washed 6 times with TBS-T, and incubated with peroxidase-conjugated secondary antibodies (Abcam, USA). Blots were detected using an enhanced chemiluminescence (ECL) detection kit (GE Healthcare, Bucks, UK)22. The original, uncropped, and unprocessed versions of Western blot images in PANC-1 and HPDE-C7 cells are shown in supplementary 1. Statistical analysis All experiments were conducted in triplicate and all data were presented as mean ± SD. Statistical analyses were performed using GraphPad Prism 10 (GraphPad Software, USA), with one-way ANOVA followed by Tukey’s post hoc test. P-value less than 0.05 was considered statistically significant. Results Analysis of PTK6 mRNA and protein levels using UALCAN The UALCAN database was used to evaluate PTK6 mRNA and protein expression in pancreatic cancer versus normal tissues. It confirmed that PTK6 mRNA is overexpressed in pancreatic cancer tissues compared to normal pancreas, supporting the rationale for targeting PTK6. Consistently, UALCAN protein data indicated elevated PTK6 levels in pancreatic cancer samples relative to normal tissue, further validating the functional relevance of PTK6 knockdown via nanoliposomes (Fig. 2A–C). Fig. 2The PTK6 expression analysis across human cancers using UALCAN. (A) TCGA cohort: PTK6 expression stratified by sample type, cancer stage, tumor grade, patient race, patient gender, patient age, drinking habit, diabetes status, metastasis, TP53 methylation, and pancreatic status. (B) Pan-cancer analysis: PTK6 mRNA expression across multiple cancer types using TCGA and CPTAC datasets. (C) CPTAC cohort: PTK6 expression analyzed by sample type, stage, grade, and activity of key signaling pathways, including Hippo, mTOR, NRF2, and RTK. The PTK6 expression analysis across human cancers using UALCAN. (A) TCGA cohort: PTK6 expression stratified by sample type, cancer stage, tumor grade, patient race, patient gender, patient age, drinking habit, diabetes status, metastasis, TP53 methylation, and pancreatic status. (B) Pan-cancer analysis: PTK6 mRNA expression across multiple cancer types using TCGA and CPTAC datasets. (C) CPTAC cohort: PTK6 expression analyzed by sample type, stage, grade, and activity of key signaling pathways, including Hippo, mTOR, NRF2, and RTK. Amplification of PTK6 via asymmetric PCR The electrophoresis result, a 100 bp fragment, confirmed the synthesis of asymmetric PCR product targeting PTK6 mRNA (Fig. 3A). Characterization of CNLAPCRP Asymmetric PCR product was encapsulated into cationic nanoliposomes, CNLAPCRP. The morphology and size distribution of the CNLAPCRP were assessed. The TEM images revealed mainly spherical particles with low levels of aggregation (Fig. 3B). DLS analysis showed that the sizes ranged from 30 to 120 nm, with an average diameter of 60 nm and PDI 0.2. The parameter (PDI) indicates a narrow size distribution, confirming the homogeneity of the liposomal formulation. The CNLAPCRP had a positive surface charge (zeta potential) of + 25 mV (Fig. 3C). Fig. 3Characterization of CNLAPCRP. (A) Agarose gel (2%) showing the fragment amplified by the asymmetric PCR; well 1 contains the replicated fragment, and well 2 shows the DNA ladder. (B) TEM image depicting the morphology of the synthesized nanoliposomes. (C) Dynamic light scattering (DLS) analysis illustrating the size distribution of the nanoliposomes ranged from 30 to 120 nm, with an average diameter of 60 nm and PDI 0.2. Characterization of CNLAPCRP. (A) Agarose gel (2%) showing the fragment amplified by the asymmetric PCR; well 1 contains the replicated fragment, and well 2 shows the DNA ladder. (B) TEM image depicting the morphology of the synthesized nanoliposomes. (C) Dynamic light scattering (DLS) analysis illustrating the size distribution of the nanoliposomes ranged from 30 to 120 nm, with an average diameter of 60 nm and PDI 0.2. To find the stability of the CNLAPCRP, their size distribution, surface charge, and release were measured during 4 weeks to assess their leakage and for how long DNA was retained in the liposomes. The results indicated the high stability during 4 weeks with near 5% leakage (Table 1). The results indicate that the formulation maintains its physicochemical properties without significant changes, confirming its short-term stability. Table 1Stability analysis of CNLAPCRP during 4 weeks.Time (Weeks)Size distribution (nm)Mean size (nm)Surface charge (mV)Release %03-12060+ 25013-13066+ 25123-13266+ 25235-13567+ 25245-13770+ 255 Table 1Stability analysis of CNLAPCRP during 4 weeks.Time (Weeks)Size distribution (nm)Mean size (nm)Surface charge (mV)Release %03-12060+ 25013-13066+ 25123-13266+ 25235-13567+ 25245-13770+ 255 Stability analysis of CNLAPCRP during 4 weeks. The effect of CNLAPCRP on cell viability To assess the impact of CNLAPCRP on cell viability, both PANC-1 (Fig. 4A) and HPDE-C7 (Fig. 4B) cells were exposed to CNLAPCRP (0, 0.1, 1, and 10 µg/mL), Asymetric PCR product alone (0, 0.1, 1, and 10 µg/mL), nanoliposome alone, and PBS as negative control for 24, 48, and 72 h. Several important findings can be understood from MTT assay. First, the best incubation time for optimal CNLAPCRP performance is 48 h. The second finding is that the behavior of cancer cells was somewhat dose-dependent for CNLAPCRP, the concentration of 10 µg/mL was better than concentrations of 1 µg/mL and 0.1 µg/mL to kill cancer cells. The third point is that CNLAPCRP performed better than the asymmetric products alone, indicating that nanoliposomes are necessary for their entry. The fourth point was that nanoliposomes alone, as a control, did not significantly reduce cell viability. But the most important finding was that CNLAPCRP had a much greater effect on cancerous cells (PANC-1) than on non-cancerous cells (HPDE-C7), indicating that CNLAPCRP acts specifically and performs its effect in a targeted manner. Fig. 4Effects of CNLAPCRP on cell viability of PANC-1 (A) and HPDE-C7 cells (B). Both PANC-1 and HPDE-C7 cells were exposed to CNLAPCRP (0, 0.1, 1, and 10 µg/mL), Asymetric PCR product alone (0, 0.1, 1, and 10 µg/mL), nanoliposome alone, and PBS as negative control for 24, 48, and 72 h. The best incubation time for optimal CNLAPCRP performance is 48 h with a dose-dependent manner. CNLAPCRP performed better than the asymmetric products alone, indicating that nanoliposomes are necessary for their entry. CNLAPCRP had a much greater effect on cancerous cells (PANC-1) than on non-cancerous cells (HPDE-C7), indicating that CNLAPCRP acts specifically and performs its effect in a targeted manner. Statistical comparisons were performed using one-way ANOVA with Tukey’s post-hoc test. Data represent mean ± SD of three independent experiments; significance: * P < 0.05, **** P < 0.0001, n = 3. Effects of CNLAPCRP on cell viability of PANC-1 (A) and HPDE-C7 cells (B). Both PANC-1 and HPDE-C7 cells were exposed to CNLAPCRP (0, 0.1, 1, and 10 µg/mL), Asymetric PCR product alone (0, 0.1, 1, and 10 µg/mL), nanoliposome alone, and PBS as negative control for 24, 48, and 72 h. The best incubation time for optimal CNLAPCRP performance is 48 h with a dose-dependent manner. CNLAPCRP performed better than the asymmetric products alone, indicating that nanoliposomes are necessary for their entry. CNLAPCRP had a much greater effect on cancerous cells (PANC-1) than on non-cancerous cells (HPDE-C7), indicating that CNLAPCRP acts specifically and performs its effect in a targeted manner. Statistical comparisons were performed using one-way ANOVA with Tukey’s post-hoc test. Data represent mean ± SD of three independent experiments; significance: * P < 0.05, **** P < 0.0001, n = 3. The effect of CNLAPCRP on apoptosis To assess the effect of CNLAPCRP on cell apoptosis, both PANC-1 (Fig. 5) and HPDE-C7 (Fig. 6) cells were exposed to CNLAPCRP (0, 0.1, 1, and 10 µg/mL), Asymetric PCR product alone (0, 0.1, 1, and 10 µg/mL), nanoliposome alone, and PBS as negative control for 48 h. Flow cytometry using Annexin V-FITC/propidium iodide staining demonstrated a dose- and time-dependent increase in apoptotic cell populations following treatment with CNLAPCRP. This finding was consistent with the MTT assay results. In this test, similar to the MTT assay, we found that the asymmetric product alone was not able to increase apoptotic cells, and its loading into nanoliposomes increased both early apoptotic and late apoptotic cells. As an important finding, we can say that CNLAPCRP has a much higher ability to induce apoptosis in cancerous cells (PANC-1) than on non-cancerous cells (HPDE-C7). Fig. 5Flow cytometry analysis on cancerous cells (PANC-1). To assess the effect of CNLAPCRP on cell apoptosis, PANC-1 cells were exposed to CNLAPCRP (0, 0.1, 1, and 10 µg/mL), Asymetric PCR product alone (0, 0.1, 1, and 10 µg/mL), nanoliposome alone, and PBS as negative control for 48 h. We demonstrated a dose- and time-dependent increase in apoptotic cell populations following treatment with CNLAPCRP. Similar to the MTT assay, we found that the asymmetric product alone was not able to increase apoptotic cells, and its loading into nanoliposomes increased both early apoptotic and late apoptotic cells. Statistical comparisons were performed using one-way ANOVA with Tukey’s post-hoc test. Data represent mean ± SD of three independent experiments; significance: * P < 0.05, **** P < 0.0001, n = 3. Flow cytometry analysis on cancerous cells (PANC-1). To assess the effect of CNLAPCRP on cell apoptosis, PANC-1 cells were exposed to CNLAPCRP (0, 0.1, 1, and 10 µg/mL), Asymetric PCR product alone (0, 0.1, 1, and 10 µg/mL), nanoliposome alone, and PBS as negative control for 48 h. We demonstrated a dose- and time-dependent increase in apoptotic cell populations following treatment with CNLAPCRP. Similar to the MTT assay, we found that the asymmetric product alone was not able to increase apoptotic cells, and its loading into nanoliposomes increased both early apoptotic and late apoptotic cells. Statistical comparisons were performed using one-way ANOVA with Tukey’s post-hoc test. Data represent mean ± SD of three independent experiments; significance: * P < 0.05, **** P < 0.0001, n = 3. Fig. 6Flow cytometry analysis on non-cancerous cells (HPDE-C7). To assess the effect of CNLAPCRP on cell apoptosis, HPDE-C7 cells were exposed to CNLAPCRP (0, 0.1, 1, and 10 µg/mL), Asymetric PCR product alone (0, 0.1, 1, and 10 µg/mL), nanoliposome alone, and PBS as negative control for 48 h. We demonstrated a dose- and time-dependent increase in apoptotic cell populations following treatment with CNLAPCRP. As an important finding, we can say that CNLAPCRP has a much higher ability to induce apoptosis in cancerous cells (PANC-1) than on non-cancerous cells (HPDE-C7). Statistical comparisons were performed using one-way ANOVA with Tukey’s post-hoc test. Data represent mean ± SD of three independent experiments; significance: *** P < 0.001, n = 3. Flow cytometry analysis on non-cancerous cells (HPDE-C7). To assess the effect of CNLAPCRP on cell apoptosis, HPDE-C7 cells were exposed to CNLAPCRP (0, 0.1, 1, and 10 µg/mL), Asymetric PCR product alone (0, 0.1, 1, and 10 µg/mL), nanoliposome alone, and PBS as negative control for 48 h. We demonstrated a dose- and time-dependent increase in apoptotic cell populations following treatment with CNLAPCRP. As an important finding, we can say that CNLAPCRP has a much higher ability to induce apoptosis in cancerous cells (PANC-1) than on non-cancerous cells (HPDE-C7). Statistical comparisons were performed using one-way ANOVA with Tukey’s post-hoc test. Data represent mean ± SD of three independent experiments; significance: *** P < 0.001, n = 3. Western blot analysis To assess the effect of CNLAPCRP on PTK6 protein level, both PANC-1 (Fig. 7A) and HPDE-C7 (Fig. 7B) cells were exposed to CNLAPCRP (0, 0.1, 1, and 10 µg/mL), Asymetric PCR product alone (0, 0.1, 1, and 10 µg/mL), nanoliposome alone, and PBS as negative control for 48 h. Analysis of Western blot images as well as corresponding histograms confirmed significant downregulation of protein PTK6 after treatment with CNLAPCRP in cancerous cells (PANC-1) compared with non-cancerous cells (HPDE-C7). Also, this test showed that the asymmetric product alone was not able to downregulation of protein PTK6, and its loading into nanoliposomes decreased PTK6 protein level. The original, uncropped, and unprocessed versions of Western blot images in PANC-1 and HPDE-C7 cells are shown in supplementary 1. Fig. 7Analysis of Western blot images and their histograms in PANC-1 (A) and HPDE-C7 (B) cells. To assess the effect of CNLAPCRP on PTK6 protein level, cells were exposed to CNLAPCRP (0, 0.1, 1, and 10 µg/mL), Asymetric PCR product alone (0, 0.1, 1, and 10 µg/mL), nanoliposome alone, and PBS as negative control for 48 h. Western blot analysis confirmed significant downregulation of PTK6 protein after treatment with CNLAPCRP in cancerous cells (PANC-1) compared with non-cancerous cells (HPDE-C7). The semi-quantitative densitometric analysis of PTK6 protein expression was done by ImageJ and PTK6 band intensities were normalized to GAPDH. Statistical comparisons were performed using one-way ANOVA with Tukey’s post-hoc test. Data represent mean ± SD of three independent experiments; significance: * P < 0.05, n = 3. Analysis of Western blot images and their histograms in PANC-1 (A) and HPDE-C7 (B) cells. To assess the effect of CNLAPCRP on PTK6 protein level, cells were exposed to CNLAPCRP (0, 0.1, 1, and 10 µg/mL), Asymetric PCR product alone (0, 0.1, 1, and 10 µg/mL), nanoliposome alone, and PBS as negative control for 48 h. Western blot analysis confirmed significant downregulation of PTK6 protein after treatment with CNLAPCRP in cancerous cells (PANC-1) compared with non-cancerous cells (HPDE-C7). The semi-quantitative densitometric analysis of PTK6 protein expression was done by ImageJ and PTK6 band intensities were normalized to GAPDH. Statistical comparisons were performed using one-way ANOVA with Tukey’s post-hoc test. Data represent mean ± SD of three independent experiments; significance: * P < 0.05, n = 3. Discussion This study focused on synthesizing CNLAPCRP, targeting PTK6 mRNA and evaluating their effects on pancreatic cancerous and non-cancerous cells. By decreasing cell viability and triggering apoptosis in a concentration- and time-dependent manner, it was shown that PTK6 silencing using this method has strong anti-tumor effects. No directly similar studies were identified; nonetheless, related research is discussed in this section. Although previous researchers have shown that PTK6 expression is increased in pancreatic cancer cells6–10, no one has been able to reduce the expression of this gene using the asymmetric product, and this is a uniquely novel finding. This approach, like an siRNA, has been able to inhibit this important gene. Unlike previous studies13,14 that primarily focused on conventional liposomal vaccine platforms or non-targeted delivery systems, our study introduces a rationally designed liposomal formulation incorporating aimed at enhancing cancer cell apoptosis. Furthermore, to our knowledge, this is the first report demonstrating apoptotic effects using this type of liposomal system. Here, we designed targeted nanocarrier system to achieve selective modulation of an oncogenic kinase in pancreatic cancer cells. Unlike previous approaches13,14 that primarily utilized chemically synthesized oligonucleotides or siRNAs, we employed asymmetric PCR to produce antisense single-stranded DNA complementary to PTK6 mRNA, which was then encapsulated into cationic nanoliposomes. We think that this combined approach not only ensures enhanced stability and cellular uptake but also allows for a direct evaluation of target-specific biological effects. Importantly, our results demonstrate that the formulated CNLAPCRP preferentially affects PANC-1 cancer cells over non-cancerous HPDE-C7 cells, highlighting both the targeting capability and selective cytotoxicity of the system. To the best of our knowledge, this is the first study to report the use of asymmetric PCR products delivered via cationic nanoliposomes to achieve functional gene knockdown and apoptosis induction in pancreatic cancer cells, providing a novel platform for gene-targeted therapy. This integrated strategy offers new mechanistic insights and could serve as a foundation for future translational studies aiming to develop more effective and selective pancreatic cancer treatments. The aberrant expression of Ptk6 has been observed in various malignant neoplasms, including breast, colon, head and neck, ovarian, prostate, lung, bladder, bile duct, pancreatic, and gastric cancers, in addition to T- and B-cell lymphoma6,7,23–27. According to UALCAN analysis, pancreatic adenocarcinoma (PAAD) tumors had significantly higher levels of PTK6 mRNA and protein than normal pancreatic tissue, indicating a pattern of consistent overexpression. Although the increase of PTK6 seems predominantly unaffected by nodal metastasis, its possible connections with critical oncogenic pathways (HIPPO, mTOR, NRF2, RTK) indicate a function in tumor growth and signaling. These findings underscore PTK6 as a potential diagnostic and therapeutic target for pancreatic cancer, necessitating further exploration of its functioning mechanisms and clinical implications. This finding is consistent with the study of Ono H. et al., which states that PTK6 is expressed at varying levels in five pancreatic cancer cell lines and is upregulated in human pancreatic adenocarcinomas9. Asymmetric PCR successfully amplified PTK6 antisense ssDNA, confirmed by a single band of the expected size on agarose gel electrophoresis, ensuring high specificity for downstream applications. The resulting ssDNA was encapsulated into cationic nanoliposomes, characterized by DLS and TEM as uniformly spherical particles with an average diameter of 50–60 nm and a positive zeta potential (+ 25 mV). These properties—small size and positive charge—facilitate efficient cellular uptake and tumor penetration, critical for overcoming the dense stromal barrier of pancreatic tumors28. The encapsulation efficiency and stability of the nanoliposomes underscore their suitability for delivering nucleic acids, protecting the PTK6 ssDNA from nuclease degradation and enhancing its bioavailability compared to naked ASOs29,30. Overall, cellular uptake of DNA–liposome complexes is not governed by a single universal pathway but rather a combination of electrostatic binding, multiple endocytic routes, and occasional membrane fusion. The relative contribution of each mechanism depends on both the physicochemical features of the liposomes and the biological properties of the target cells. Understanding which pathway predominates in a given system is essential for optimizing transfection efficiency and designing next-generation lipid-based gene delivery vectors. The MTT assay showed significant viability reduction in PANC-1 cells treated with PTK6 antisense-loaded nanoliposomes, with the most significant effect at 10 µg/mL after 48 h (p < 0.05 compared to 0.1 µg/mL). This is in line with what PTK6 does to help cells survive and invade, since silencing it stops ERK1/2 signaling, which is a key cancer-causing pathway in pancreatic cancer9. Flow cytometry using Annexin V-FITC/propidium iodide staining further confirmed a dose- and time-dependent increase in apoptosis, peaking at 48 h with 100 µg/mL and 10 µg/mL concentrations (p < 0.05). These results suggest that PTK6 knockdown induces programmed cell death, likely via caspase-8 activation, as reported in gemcitabine-related studies31. A modest recovery in cell viability and decreased apoptosis at 72 h, however, point to potential limits in long-term effectiveness. This rebound might be the consequence of the slow degradation of antisense ssDNA within nanoliposomes32. Additionally, compensatory activation of survival pathways, such as AKT or STAT3, may enable tumor cells to resist apoptosis and recover viability post-PTK6 knockdown33. Compared to other gene therapy approaches, nanoliposomes offer significant advantages. Unlike viral vectors, which risk immunogenicity and insertional mutagenesis, nanoliposomes exhibited low cytotoxicity and efficient transfection34. Their proficiency in engaging with biological systems, reduced potential for eliciting an immune response, stability, adaptability in surface modification, and feasibility for large-scale production render them attractive35. They are appealing due to their ability to interact with biological systems, decreased risk of triggering an immune response, stability, versatility in surface modification, and viability for large-scale manufacturing35. Despite these strengths, limitations remain. The 72-hour rebound effect underscores the need for nuclease-resistant ssDNA backbones or PEGylated nanoliposomes to prolong efficacy. As demonstrated by PTK6’s role in gemcitabine sensitivity, in vivo validation in pancreatic cancer xenografts is crucial to confirm the therapeutic effect. Therapeutic approaches will be further improved by mechanistic research clarifying PTK6’s downstream ERK1/2 targets and compensatory AKT/STAT3 signaling. Conclusion In conclusion, CNLAPCRP effectively reduced PANC-1 cell viability, induces apoptosis, and decreased ptk6 protein level, offering a biocompatible, targeted alternative to viral vectors and other carriers for pancreatic cancer therapy. Electronic Supplementary Material Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1